| Application no. and date | 17700906.5 (espacenet) (Federated) (European Patent Register), 20170105 | | Patent/reg. no. and date | DK/EP 3400065, 20251217 | | Publication date | 20181114 | | Priority no. and date | EP 16150635, 20160108, EP 16179293, 20160713, EP 16191482, 20160929 | | EP pub. no. and date |
EP 3400065 20181114 | | Effective date | | | Applicant/owner | Ascendis Pharma Growth Disorders A/S, Tuborg Boulevard 12, 2900 Hellerup, DK | | Applicant ref. no. | V501600DK00 | | Inventor | SPROGØE, Kennett, 2900 Hellerup, DK,
Rau, Harald,
69120 Heidelberg, DE,
Hersel, Ulrich,
69120 Heidelberg, DE,
CLEEMANN, Felix,
69120 Heidelberg, DE,
Rasmussen, Caroline Elisabeth, 2900 Hellerup, DK | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 47/60 (2017.01) , A61K 47/68 (2017.01) , A61P 19/08 (2006.01) | | Title | CNP-agonister med kontrolleret frigivelse og reducerede bivirkninger | | Int. application no. | EP2017050224 | | Int. publication no. | WO2017118707 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
